-
31 votes
-
Amid backlash, US FDA changes course over shortage of weight-loss drugs
23 votes -
Weight loss drugs appear to be having an effect at the population level
24 votes -
Kentucky sues Express Scripts, alleging it had a role in the deadly opioid addiction crisis
15 votes -
US Federal Trade Commission sues insulin middlemen, saying they pocket billions while patients face high costs
37 votes -
Epilepsy drug Sulthiame could help people with sleep apnea get a good night's rest, Swedish study finds
11 votes -
The growing scientific case for using Ozempic and other GLP-1s to treat opioid, alcohol, and nicotine addiction
39 votes -
The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine
29 votes -
A new way to prevent HIV delivers dramatic results in trial
17 votes -
US Supreme Court rejects liability shield at center of Purdue Pharma settlement
31 votes -
Novo Nordisk is to invest more than $4bn in US manufacturing as it battles to keep up with booming demand for its obesity and diabetes drugs Wegovy and Ozempic
9 votes -
The opaque industry secretly inflating prices for prescription drugs
18 votes -
Rapid UTI test that cuts detection time to forty-five minutes awarded Longitude prize – could herald sea change in antibiotic use by identifying correct treatments
26 votes -
mRNA melanoma vaccine halves the risk of death and recurrence
16 votes -
Scientists pinpoint driver of IBD and other disorders; work under way to adapt existing drugs
14 votes -
US, European nations consider vaccinating workers exposed to bird flu
9 votes -
US biotech executive sentenced to seven years in jail for COVID test fraud
18 votes -
The fight for abortion pills – In the US, UK and around the world, the backlash against safe, at-home abortion medication is growing
26 votes -
There is no evidence that CBD products reduce chronic pain, and taking them is a waste of money and potentially harmful to health, new research finds
58 votes -
A pill to make exercise obsolete (2017)
19 votes -
The war on recovery: how the US is sabotaging its best tools to prevent deaths in the opioid epidemic
17 votes -
Cystic fibrosis breakthrough has given patients a chance to live longer
18 votes -
US prescription market hamstrung for nine days (so far) by ransomware attack
39 votes -
A US drugmaker’s feud with the DEA is exacerbating the ADHD meds crisis
36 votes -
Finland used to have one of the highest suicide rates in the world – how the country halved it and saved countless lives
28 votes -
Niacin has long been a public health darling. But an excess could be bad for the heart, study suggests.
15 votes -
Research at the heart of a US lawsuit against the abortion pill has been retracted
28 votes -
EBay will pay $59 million settlement over pill presses sold online as US undergoes overdose epidemic
10 votes -
The man in room 117 – Andrey Shevelyov would rather live on the street than take antipsychotic medication. Should it be his decision to make?
21 votes -
Pharma bro Martin Shkreli goes ballistic on US federal appeals court for upholding lifetime ban from pharma industry
41 votes -
Gene therapy allows an 11-year-old boy to hear for the first time
30 votes -
Why are antidepressants so popular in Iceland? | Mindset
6 votes -
Psychoactive drug ibogaine effectively treats traumatic brain injury in special ops military vets
31 votes -
Scientists hail new antibiotic that can kill drug-resistant bacteria
13 votes -
Aripiprazole (Abilify and generic brands): risk of pathological gambling
14 votes -
A quiet merger trial between antitrust enforcers and a pharma data giant called IQVIA reveals how bro-style executives control US medical data
13 votes -
How two US pharmacists figured out that oral phenylephrine decongestants don’t work
32 votes -
Moderna, Merck vaccine with Keytruda cuts risk of deadly skin cancer returning in half, data says
9 votes -
New lifesaving malaria vaccines need to be available now
7 votes -
The US Supreme Court will rule on limits to the use of Mifeprestone, a commonly used abortion medication
16 votes -
Novo Nordisk suggested to senior UK government officials that they could “profile” benefit claimants – those who are most likely to return to the labour market
17 votes -
First malaria vaccine slashes early childhood mortality
12 votes -
Adderall risks: Much more than you wanted to know (2017)
35 votes -
The Ozempic effect is coming for everything from kidney to heart disease treatments
12 votes -
New pill helps COVID smell and taste loss fade quickly
19 votes -
Life-changing cystic fibrosis treatment wins US$3-million Breakthrough Prize
15 votes -
There's hope for the US opioid crisis — but politics stands in the way
8 votes -
The hidden system of legal kickbacks shaping the US prescription drug market
10 votes -
Phenylephrine, a common decongestant in medicines is no better than a placebo when taken orally, says a US FDA advisory panel
by Wes Davis A key cold medicine ingredient is basically worthless The FDA’s 16-member advisory panel unanimously voted yesterday that oral phenylephrine, a common active ingredient in cold...
by Wes Davis
A key cold medicine ingredient is basically worthless
The FDA’s 16-member advisory panel unanimously voted yesterday that oral phenylephrine, a common active ingredient in cold medications, is no better than a placebo for treating congestion.
Link to the article
The call by the panel sets up potential FDA action that could force the removal of certain over-the-counter medications containing the ingredient — including certain formulations of Mucinex, Sudafed, Tylenol, and NyQuil — from store shelves.
But FDA may hold off for many months, pending contested findings by drug makers and other considerations.Data
Newer data from studies the panel says are more consistent with modern clinical trial standards showed phenylephrine simply “was not significantly different from placebo” in the recommended dosage, including trials from 2007 that the FDA had reviewed when considering the drug after a citizen petition prompted it to do so.
Bioavailability
The panel cited the drug’s low bioavailability, a term referring to qualities that allow the drug to be absorbed by the human body, as the main reason the drug should be removed from the market.
Jennifer Schwartzott said the drug “should have been removed from the market a long time ago,” while Dr. Stephen Clement said that although the drug itself isn’t dangerous, its usage by patients should be considered unsafe because it potentially delays actual treatment of disease symptoms.
Alternative
The panel cited pseudoephedrine as an effective alternative though while it’s technically available without a prescription, you must talk to a pharmacist to get it because, in large quantities, it can be used to make methamphetamines.
50 votes -
Ozempic cuts alcohol cravings. Liquor companies aren’t ready.
30 votes